How to Get Zepbound in Maryland

What Zepbound Is and Why It Requires a Prescription

Zepbound is the brand name for tirzepatide, a dual GIP/GLP-1 receptor agonist that Eli Lilly developed for chronic weight management. The FDA approved it in November 2023 for adults with obesity (BMI ≥30) or overweight (BMI ≥27) who have at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia.

Tirzepatide works by activating two incretin hormone receptors simultaneously. The glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor both play roles in appetite regulation, gastric emptying, and glucose metabolism. This dual mechanism distinguishes tirzepatide from single-receptor GLP-1 agonists like semaglutide 1.

In the SURMOUNT-1 trial (N=2,539), participants receiving tirzepatide 15 mg achieved a mean body weight reduction of 22.5% at 72 weeks, compared to 3.1% with placebo. The 10 mg dose produced 21.4% weight loss, and the 5 mg dose produced 16.0% 1. These results exceeded those seen with any previously approved anti-obesity medication at the time of publication. Over 90% of participants on the 10 mg and 15 mg doses lost at least 5% of their body weight.

Because tirzepatide carries risks including pancreatitis, gallbladder disease, and a boxed warning regarding medullary thyroid carcinoma in rodent studies, it is classified as prescription-only 2. No pharmacy in Maryland can dispense it without a valid prescription from a licensed provider.

Telehealth Prescribing Rules in Maryland

Maryland law permits licensed prescribers to evaluate patients and write prescriptions via telehealth without requiring an initial in-person visit. This applies to Zepbound. A Maryland-based or Maryland-licensed provider can conduct a synchronous video or audio consultation, assess eligibility, order labs, and transmit a prescription to any pharmacy in the state.

The Maryland Board of Physicians requires that a telehealth encounter meet the same standard of care as an in-person visit 3. For weight management prescriptions, that means documenting BMI, medical history, contraindications screening, and a treatment plan. Providers must hold an active Maryland medical license or be authorized under an interstate compact.

Several national telehealth platforms now serve Maryland patients seeking tirzepatide prescriptions. These platforms typically handle lab ordering, insurance verification, and pharmacy coordination within a single workflow. Wait times vary, but most platforms complete the initial evaluation within 48 to 72 hours of intake submission.

Maryland's telehealth parity law (Health-General Article §19-143) also requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, which means the consultation cost should not increase simply because you choose a virtual appointment 4.

Who Can Prescribe Zepbound in Maryland

Four types of licensed clinicians in Maryland hold prescriptive authority that includes Zepbound: physicians (MD and DO), nurse practitioners (NP), physician assistants (PA), and, in specific clinical settings, certified nurse-midwives (CNM). Each operates under the oversight structure defined by the Maryland Board of Physicians or the Maryland Board of Nursing.

Nurse practitioners in Maryland gained full practice authority in 2024, meaning they can prescribe independently without a collaborative agreement after meeting specified experience thresholds. PAs still require a delegation agreement with a supervising physician, though the physician does not need to be physically present at the time of prescribing.

For Zepbound specifically, any of these providers can write the prescription as long as they perform an appropriate clinical evaluation, confirm the patient meets FDA-approved indications, and document the medical necessity. The Endocrine Society's 2023 clinical practice guideline on pharmacological management of obesity recommends that prescribers monitor patients on GIP/GLP-1 receptor agonists every 4 to 12 weeks during dose titration 5.

Labs and Medical Evaluation Before Starting

Before prescribing tirzepatide, most Maryland clinicians order a standard metabolic workup. This is not a regulatory mandate specific to Maryland but reflects the standard of care outlined in the Zepbound prescribing information and professional guidelines.

A typical pre-treatment lab panel includes:

• Comprehensive metabolic panel (CMP): assesses kidney function (eGFR, creatinine), liver enzymes (ALT, AST), and fasting glucose
• Hemoglobin A1c: screens for pre-diabetes or undiagnosed type 2 diabetes
• Lipid panel: baseline cholesterol and triglyceride levels, since tirzepatide has demonstrated lipid-modifying effects
• Thyroid function (TSH): required given the boxed warning about thyroid C-cell tumors in animal models 2
• Pregnancy test: for women of reproductive age, as tirzepatide is contraindicated in pregnancy

Some providers also order a lipase level at baseline, which serves as a reference point should pancreatitis symptoms develop during treatment. The American Association of Clinical Endocrinology (AACE) recommends screening for personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2 (MEN 2) before initiating any GLP-1 receptor agonist 6.

Labs can be ordered through any CLIA-certified laboratory in Maryland. Many telehealth platforms partner with national lab networks (Quest Diagnostics, Labcorp) that have draw sites throughout the state, including locations in Baltimore, Silver Spring, Columbia, and Annapolis.

Maryland Medicaid and Insurance Coverage

Maryland Medicaid covers Zepbound for chronic weight management, but prior authorization is required. This means your prescriber must submit documentation proving medical necessity before Medicaid will approve the claim. The typical turnaround for a Medicaid prior authorization decision in Maryland is 24 to 72 hours for standard requests and 24 hours for urgent requests.

Prior authorization documentation generally requires:

• Confirmed BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity
• Documentation of failed lifestyle modifications (diet and exercise) over at least 3 to 6 months
• Lab results supporting the diagnosis
• A treatment plan that includes nutritional counseling or behavioral therapy alongside the medication

Commercial insurers in Maryland vary widely in their coverage of Zepbound. Some plans cover it under the pharmacy benefit with a specialty tier copay. Others exclude anti-obesity medications entirely, which is permitted under Maryland insurance law for self-funded employer plans regulated by ERISA rather than state mandates 7.

The Treat and Reduce Obesity Act has been reintroduced in Congress multiple times but had not passed as of early 2026. If enacted, it would require Medicare Part D coverage of anti-obesity medications, which would also affect Medicare Advantage plans operating in Maryland.

Eli Lilly offers a savings card program for commercially insured patients, potentially reducing the out-of-pocket cost to as low as $25 per month for eligible individuals. Patients without insurance or whose plans exclude Zepbound face a list price of approximately $1,060 per month, though pricing is subject to change 2.

Pharmacy Options: Retail, Specialty, and 503A Compounding

Maryland residents have three pharmacy pathways for filling a Zepbound prescription: retail pharmacies, specialty pharmacies, and 503A compounding pharmacies.

Retail pharmacies (CVS, Walgreens, Rite Aid, independent pharmacies) can dispense brand-name Zepbound. Stock availability fluctuates with demand. During periods of high demand, some pharmacies may need to order the medication with a 2- to 5-day lead time. Calling ahead to confirm availability is standard practice.

Specialty pharmacies handle medications that require special storage, handling, or clinical monitoring. Some insurers mandate that Zepbound be filled through a designated specialty pharmacy, which may offer home delivery throughout Maryland.

503A compounding pharmacies in Maryland can prepare compounded tirzepatide when a licensed prescriber writes a patient-specific prescription. Under federal law (section 503A of the Federal Food, Drug, and Cosmetic Act), a 503A pharmacy compounds medications based on individual prescriptions and must be licensed in the state where the patient resides 8. Maryland's Board of Pharmacy licenses and inspects compounding pharmacies operating within the state.

Compounded tirzepatide is not the same as brand-name Zepbound. The FDA has placed tirzepatide on and off its drug shortage list, and the legal status of compounded versions is subject to change based on shortage determinations. Patients considering compounded tirzepatide should confirm with their provider that the compounding pharmacy uses USP 797-compliant sterile compounding practices 8.

Dose Titration and What to Expect

Zepbound uses a structured dose escalation schedule designed to minimize gastrointestinal side effects. The FDA-approved titration is:

• Weeks 1 through 4: 2.5 mg once weekly (initiation dose, not a maintenance dose)
• Weeks 5 through 8: 5 mg once weekly
• Weeks 9 through 12: 7.5 mg once weekly (if tolerated)
• Weeks 13 through 16: 10 mg once weekly
• Week 17 onward: 12.5 mg or 15 mg once weekly, based on response and tolerability

Not every patient reaches 15 mg. In SURMOUNT-1, clinically meaningful weight loss occurred across all dose levels, including the 5 mg arm, which showed 16.0% mean weight reduction at 72 weeks 1.

The most common side effects during titration are nausea (reported by 24% to 33% of participants in clinical trials), diarrhea, constipation, and injection site reactions. These effects are typically mild to moderate and tend to diminish after the first 4 to 8 weeks of each dose step 2.

Maryland providers generally schedule follow-up appointments every 4 weeks during the first 16 weeks of treatment, then every 8 to 12 weeks once a stable dose is reached. Weight, blood pressure, heart rate, and side effect monitoring are standard at each visit.

Transferring a Prescription to Maryland

If you already hold a valid Zepbound prescription from another state, you can transfer it to a Maryland pharmacy. The transferring pharmacy contacts the receiving Maryland pharmacy directly to complete the transfer. Maryland accepts prescription transfers from all 50 states for non-controlled substances, and tirzepatide is not a controlled substance.

For telehealth patients who relocate to Maryland, the prescribing provider must either hold a Maryland medical license or refer the patient to a Maryland-licensed provider. Interstate medical licensure compact (IMLC) member states allow expedited licensure, and Maryland is a member of this compact 9.

Patients transferring care should bring their complete medication history, including current dose, titration history, and most recent lab work, to their new Maryland provider. This avoids unnecessary repeat testing and prevents gaps in treatment.

Timeline: From Consultation to First Injection

The timeline from initial consultation to administering the first Zepbound injection in Maryland typically follows this sequence:

Days 1 to 3: Complete telehealth or in-person intake. Provide medical history, current medications, and body measurements. The provider orders labs if not already completed.

Days 3 to 7: Lab results return. Provider reviews results, confirms eligibility, and submits the prescription. If prior authorization is required, the provider's office submits the request simultaneously.

Days 7 to 14: Prior authorization decision (if applicable). Pharmacy receives and processes the prescription. For brand-name Zepbound, pharmacy confirms stock or orders the medication.

Days 10 to 21: Medication is available for pickup or delivered to your home. The provider or pharmacist reviews injection technique, storage instructions (refrigerate at 36 to 46°F), and side effect management.

This timeline compresses for patients who have recent labs already completed and whose insurance does not require prior authorization. Some patients receive their medication within 7 days of the initial consultation. Delays most commonly occur at the prior authorization stage.

Monitoring and Long-Term Management

Ongoing monitoring while taking Zepbound in Maryland follows the same evidence-based protocols used nationally. The AACE 2023 obesity algorithm recommends reassessing weight loss response at 12 to 16 weeks on the maximum tolerated dose 6. A response of less than 5% total body weight loss at that point may prompt a discussion about dose adjustment or alternative therapies.

Laboratory monitoring during treatment typically includes repeating the CMP and A1c every 6 to 12 months. For patients with pre-existing type 2 diabetes, more frequent glucose monitoring is appropriate because tirzepatide significantly reduces blood glucose and may necessitate adjustments to concurrent diabetes medications. In the SURPASS-1 trial, 33.9% of participants on tirzepatide 15 mg achieved an A1c below 5.7%, which is in the non-diabetic range 10.

Maryland providers should also monitor for gallbladder-related symptoms during rapid weight loss. The SURMOUNT-1 trial reported cholelithiasis in approximately 0.6% of tirzepatide-treated participants compared to 0% in the placebo group 1. Patients experiencing right upper quadrant pain, especially after fatty meals, should report symptoms promptly.

The Zepbound prescribing label does not specify a maximum treatment duration. Weight management with tirzepatide is intended as long-term therapy, and discontinuation studies suggest weight regain following cessation. The SURMOUNT-4 trial demonstrated that participants who switched from tirzepatide to placebo after 36 weeks regained approximately 14% of body weight over the subsequent 52 weeks, while those who continued tirzepatide lost an additional 5.5% 11.